Final Program

TUESDAY • MAY 17 263
P404
P405
P406
P407
P408
P409
P410
P411
P412
MUC5B Genotype Does Not Affect Cough Severity In Fibrotic
Lung Diseases/P. Saunders, C. Stock, S. Kingston, P.L.
Molyneaux, M.G. Belvisi, M. Kokosi, A.U. Wells, E. Renzoni, T.M.
Maher, London, United Kingdom, p.A4986
Relationship of Serum Sodium Level to Outcomes in Patients
with Interstitial Lung Disease/P.R. Yeturu, D. Kurbanov, C.
Cherian, J. Pang, M.J. Fazzari, G. Nair, Mineola, NY, p.A4987
Functional Respiratory Imaging (FRI) in IPF: Regional
Information Matters/W. Vos, C. Van Holsbeke, F. Ferreira, J. De
Backer, J.G. Goldin, S. Porter, W. De Backer, Kontich, Belgium,
p.A4988
Survival in Interstitial Lung Disease with Possible Usual
Interstitial Pneumonia by High Resolution Computed
Tomography/C.T. Lee, J.M. Oldham, J.H. Chung, S. Montner, E.
Valenzi, L.J. Witt, L.W. Chen, S. Hsu, M.E. Strek, I. Noth, R. Vij,
Chicago, IL, p.A4989
Correlation of DLCO Components (Dm and Vc) with High
Resolution Computed Tomography and Their Prognostic
Impact in Idiopathic Pulmonary Fibrosis/T.F. Gille, L. Moya, M.
Boubaya, G. Bertrand, D. Valeyre, P.Y. Brillet, C. Lamberto, C.
Planes, H. Nunes, Bobigny, France, p.A4990
Progression of Pulmonary Hypertension in Idiopathic
Pulmonary Fibrosis with Mostly Mild to Moderate
Restriction/R. Teramachi, H. Taniguchi, Y. Kondoh, T. Kimura, K.
Kataoka, T. Matsuda, T. Yokoyama, A. Suzuki, T. Furukawa, Seto,
Japan, p.A4991
Diagnosis by Multi Disciplinary Discussion of Idiopathic
Interstitial Pneumonias in a Real World; Japanese Multi Center
Cohort Study/Y. Inoue, M. Kitaichi, M. Akira, T. Johkoh, A.
Hebisawa, I. Yamadori, T. Arai, C. Sugimoto, A. Matsumuro, M.
Hirose, K. Tachibana, T. Kasai, W.D. Wallace, D.M. Hansell, W.D.
Travis, Osaka, Japan, p.A4992
Spectrum of Idiopathic Pulmonary Fibrosis Severity in Clinical
Practice: Implications for Clinical Trial Feasibility and
Design/D. Macaulay, S.D. Nathan, Y. Yu, E. Terasawa, New York,
NY, p.A4993
Demographic and Clinical Characteristics of Patients Treated
with Pirfenidone in the US/K. Raimundo, A. Farr, W. Chou, South
San Francisco, CA, p.A4994
P413 Effect of Continued Treatment with Pirfenidone Following a ³
Relative Decline in Percent Predicted Forced Vital Capacity in
Patients with Idiopathic Pulmonary Fibrosis (IPF)/S.D. Nathan,
C. Albera, U. Costabel, I. Glaspole, M. Glassberg, L. Lancaster,
D.J. Lederer, C.A. Pereira, J. Swigris, B.-M. Day, W. Chou, A.U.
Wells, Falls Church, VA, p.A4995
P414
P415
Residual Volume-Corrected Forced Vital Capacity Change: A
More Accurate Indicator of Outcomes in IPF?/S.D. Nathan, N.
Weir, S.A. Stayrook, C.S. King, S. Ahmad, O.A. Shlobin, A.W.
Brown, Falls Church, VA, p.A4996
CPI and DLCO Parameters Identifying Patients at Risk of Acute
Exacerbation of IPF/E. Fraser, R. Hoyles, L.P. Ho, Oxford, United
Kingdom, p.A4997
Facilitator:
P416
P417
P418
P419
P420
P421
P422
P423
P424
P425
P426
P427
K.K. Brown, MD, Denver, CO
Benefits of Young Donor Adipose-Derived Mesenchymal Stem
Cell Therapy in the Rescue of Bleomycin-Induced Pulmonary
Fibrosis in an Aged Mouse Model/G.A. Rubio, X. Xia, S.
Pereira-Simon, S.J. Elliot, M. Glassberg, Miami, FL, p.A4998
Diagnostic Significance of Biomarkers for Chronic Fibrosing
Idiopathic Interstitial Pneumonias (Usual Interstitial
Pneumonia Vs Non-Specific Interstitial Pneumonia)/M. Kato, S.
Sasaki, K. Nakamura, N. Arano, T. Takeshige, S. Kuriyama, K.
Muraki, O. Nagashima, Y. Yoshioka, S. Tominaga, K. Takahashi,
Chiba, Japan, p.A4999
Relationship Between Nintedanib Exposure, Patient
Characteristics and Clinical Efficacy in Patients with Idiopathic
Pulmonary Fibrosis/U. Schmid, B. Weber, C. Dallinger, L.
Richeldi, C. Hallmann, G. Raghu, M. Freiwald, Biberach an der
Riss, Germany, p.A5000
Serum Decorin as a Possible Prognostic Biomarker in Patients
with Acute Exacerbation of Idiopathic Pulmonary Fibrosis/T.
Nikaido, Y. Tanino, N. Fukuhara, K. Misa, Y. Sato, R. Togawa, Y.
Suzuki, M. Uematsu, A. Fukuhara, S. Sato, J. Saito, X. Wang, M.
Munakata, Fukushima, Japan, p.A5001
Implications of Pulmonary Physiology and Exercise Testing
Results in Idiopathic Pulmonary Fibrosis (IPF) in a Real World
Cohort/C. Sharp, G. Dixon, A. Edwards, H. Adamali, A.B. Millar,
Bristol, United Kingdom, p.A5002
Characteristics and Accuracy of Internet Health Information for
Idiopathic Pulmonary Fibrosis/J.H. Fisher, D. O’Connor, A.M.
Flexman, S. Shapera, C.J. Ryerson, Toronto, Canada, p.A5003
Baseline Pulmonary Function Test Predicts Survival: Analysis
from the Australian IPF Registry/H. Jo, I. Glaspole, N. Goh, P.
Hopkins, Y. Moodley, P. Reynolds, H. Walters, C. Zappala, H.
Allan, S. Chapman, W. Cooper, S. Ellis, C. Grainge, G. Keir, A.
Mahar, T.J. Corte, Camperdown, Australia, p.A5004
Human Epididymis Protein 4 Is a Novel Biomarker for Chronic
Fibrosing Interstitial Pneumonias/M. Masuo, Y. Miyazaki, T.
Fujie, N. Inase, M. Nakamura, K. Ohbo, Tokyo, Japan, p.A5005
Digital Clubbing Is Associated with Higher Serum KL-6 Levels
and Lower Pulmonary Function in Patients with Interstitial
Lung Disease/K. Shiraishi, T. Jinta, N. Nishimura, R. Tsugitomi, T.
Tanigawa, H. Nakaoka, K. Okafuji, A. Kitamura, Y. Tomishima, T.
Tamura, G.A. Deshpande, N. Chohnabayashi, Tokyo, Japan,
p.A5006
Airway Expression of Transient Receptor Potential Channels in
Idiopathic Pulmonary Fibrosis/N.X. Hutchinson, S. Wozniak, A.
Gibbs, A.J. Tonks, B. Hope-Gill, Cardiff, United Kingdom, p.A5007
Using microCT to Quantify the Compliance of Lungs in a
Bleomycin-Induced Pulmonary Fibrosis Rat Model/S. Siddiqui,
Y. Xin, H. Profka, S. Kadlecek, R.R. Rizi, Philadelphia, PA, p.A5008
Comparative Analysis Between Pulmonary Fibrosis Idiopathic
and Systemic Sclerosis Regarding Six-Minute Walk Test and
Respiratory Function Test/M. Pimentel, L. Valentine, K.M. Da
Silva, A. Maiworm, R. Rufino, C.H.D. Costa, Rio de Janeiro, Brazil,
p.A5009
TUESDAY MORNING
ATS 2016 • San Francisco